Site is Being Upgraded

Molecular therapy for pulmonary arterial hypertension: Fenofibrate inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 11.23 pm

Molecular therapy for Anti-ageing and Lifespan extension:  Atorvastatin, a medication used in the treatment of cardiovascular disease,  increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan via down regulation of its target gene, 10/February/2018, 11.15 pm
February 10, 2018
Molecular therapy for Stroke:  Pantoprazole (brand name: Protinix), a drug used in the treatment of stomach and duodenal ulcers, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 10/February/2018, 11.36 pm
February 10, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: Fenofibrate inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3


Significance of the study:  

This study suggests, for the first time, that  Fenofibrateby increasing the expression of its target gene, it may decrease, in dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, pharmacological formulations encompassing “Fenofibrate or its analogues, either alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension (Figure 2). Together, this study suggests that, by treating pulmonary hypertensive patients with Fenofibrateone may prevent pulmonary arterial hypertension

Figure 1. Mechanistic insights into how  Fenofibrate inhibits the development of pulmonary hypertension through regulation of its target genes

Figure 2. The chemical structure of Fenofibrate.


Details of the research findings: 

Idea Proposed/Formulated by:

Dr L Boominathan Ph.D.

Undisclosed mechanistic information: How Fenofibrate decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L., Molecular therapy for pulmonary arterial hypertension: Fenofibrate inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 11.25 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.